Literature DB >> 31436213

Commentary: Role of PASCAL and optical coherence tomography angiograpgy in the treatment of diffuse unilateral subacute neuroretinitis caused by large live motile worm.

Chitaranjan Mishra1.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31436213      PMCID: PMC6727696          DOI: 10.4103/ijo.IJO_757_19

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Different nematodes have been associated with diffuse unilateral subacute neuroretinitis (DUSN) including Toxocara canis, Ancylostoma caninum, Strongyloides stercoralis, Ascaris lumbricoides, and Baylisascaris procyonis.[1] The clinical features of DUSN include subretinal tracks, small yellow-white spots on retina, altered internal limiting membrane (ILM) reflex, vitritis, vasculitis, retinal edema, live worm, alterations of the retinal pigment epithelium, narrowed retinal vessels, and optic disc atrophy especially in late phases.[2] The early signs of DUSN are often mistaken for entities that cause focal chorioretinitis, including toxoplasmosis, histoplasmosis, sarcoidosis, white dot syndromes, nonspecific optic neuritis, and papillitis. The late stage of DUSN is often mistaken for posttraumatic chorioretinopathy, occlusive vascular disease, sarcoidosis, toxic retinopathy, or retinitis pigmentosa.[1] Graeff-Teixeira et al. has reported maximum patients in their series to be below 2 year age, emphasizing the prevalence of DUSN in very young age group.[3] According to previous literature, in about 25–40% cases the live worm is identified.[14] The work by Cherukuri et al. is appreciated since they were able to restrict and neutralize the worm away from the fovea.[5] Pattern scanning laser photocoagulation was helpful in quick and accurate delivery of the laser spots so that foveal migration of the worm and consequent difficulty in management was prevented. The identification and laser photocoagulation (PHC) of the live worm in DUSN is crucial and there have been reports of better visual outcome even without the identification of the worm.[1] However, laser PHC in the early phase of the disease is the key for better visual prognosis since laser PHC of the worm in late phase DUSN may not be associated with much visual improvement.[6] Thiabendazole and corticosteroids are useful, especially in cases associated with vitritis or possible disruption of blood retinal barrier, even in absence of the worms.[1] Use of a contact lens, wide angle fundoscopy, wide angle optical coherence tomography (OCT) may help in diagnosis of the worm.[4] Additional documentation with optical coherence tomography angiography (OCTA) in the present study throws some light on the increased diagnostic accuracy and rate of worm identification in cases with DUSN, as has already been described by Kalevar and Jumper.[4] With the availability of higher resolution and ultra-widefield OCTA, our capability to diagnose and understand DUSN will likely improve. There has been description of spectral domain OCT demonstrating reduced retinal nerve fiber layer thickness and central macular thickness, enhanced depth imaging OCT demonstrating no change in choroidal thickness, and electrophysiological tests reporting functional evidence of both inner and outer retinal dysfunction.[78] However, large-scale studies need to validate these tests and biomarkers in diagnosing and prognosticating DUSN. Finally, public health awareness about the clinical signs and high index of suspicion about DUSN among treating physicians will help in early diagnosis, prompt treatment, and better visual prognosis of this disease entity. Proper documentation and discussion of management protocols among peer group enriches the collective academical knowledge.
  8 in total

1.  Structural and functional retinal changes in eyes with DUSN.

Authors:  Diego Vezzola; Nacima Kisma; Anthony G Robson; Graham E Holder; Carlos Pavesio
Journal:  Retina       Date:  2014-08       Impact factor: 4.256

Review 2.  Diffuse unilateral subacute neuroretinitis.

Authors:  J Fernando Arevalo; Fernando A Arevalo; Reinaldo A Garcia; Carlos Alexandre de Amorim Garcia Filho; Carlos Alexandre de Amorim Garcia
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2012-12-18       Impact factor: 1.402

3.  Clinical features of 121 patients with diffuse unilateral subacute neuroretinitis.

Authors:  Carlos Alexandre de Amorim Garcia Filho; Alexandre Henrique Bezerra Gomes; Ana Claudia M de A Garcia Soares; Carlos Alexandre de Amorim Garcia
Journal:  Am J Ophthalmol       Date:  2012-01-14       Impact factor: 5.258

4.  Late-stage diffuse unilateral subacute neuroretinitis: photocoagulation of the worm does not improve the visual acuity of affected patients.

Authors:  Carlos Alexandre de A Garcia; Alexandre H B Gomes; Raul N G Vianna; João Pessoa Souza Filho; Carlos A de A Garcia Filho; Fernando Oréfice
Journal:  Int Ophthalmol       Date:  2006-06-19       Impact factor: 2.031

Review 5.  Update on Baylisascariasis, a Highly Pathogenic Zoonotic Infection.

Authors:  Carlos Graeff-Teixeira; Alessandra Loureiro Morassutti; Kevin R Kazacos
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

6.  Optical coherence tomography angiography of diffuse unilateral subacute neuroretinitis.

Authors:  Ananda Kalevar; J Michael Jumper
Journal:  Am J Ophthalmol Case Rep       Date:  2017-06-22

7.  Role of PASCAL and optical coherence tomography angiograpgy in the treatment of diffuse unilateral subacute neuroretinitis caused by large live motile worm.

Authors:  Navya Cherukuri; Bhavik Panchal; Hrishikesh Kaza; Shreyansh Doshi; Avinash Pathengay
Journal:  Indian J Ophthalmol       Date:  2019-09       Impact factor: 1.848

8.  Evaluation of patients with diffuse unilateral subacute neuroretinitis by spectral domain optical coherence tomography with enhanced depth imaging.

Authors:  Rodrigo F Berbel; Antonio Marcelo B Casella; Eduardo C de Souza; Michel E Farah
Journal:  Clin Ophthalmol       Date:  2014-06-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.